Invivyd, Inc.
IVVDDrugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Sep 30, 2026
12dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
Phase 3 — VYD2311
For Prevention of symptomatic COVID-19. Invivyd completed enrollment in the DECLARATION Phase 3 trial for VYD2311, a monoclonal antibody for COVID-19 prevention. Top-line results are expected in late Q3 2026.
SourceHow IVVD's past catalysts played out
No drugs found in this phase.
Full breakdown — the signals behind the verdict
Frequently asked questions
When is Invivyd, Inc.'s next FDA catalyst?→
Invivyd, Inc.'s (IVVD) next tracked catalyst is a Phase 3 expected September 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IVVD biotech catalysts?→
Add IVVD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Invivyd, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.